Affibody AB, of Solna, Sweden, said it has signed a research license and product option agreement regarding IL-17-targeting molecules in ophthalmology with an unnamed partner. The company is developing four programs. The first three are therapeutics for the prevention of Alzheimer's disease, autoimmune diseases and psoriasis, respectively. The fourth program is a diagnostic imaging program that is directed primarily toward metastatic breast cancer.